Journal article

Aberrant Inclusion of a Poison Exon Causes Dravet Syndrome and Related SCN1A-Associated Genetic Epilepsies

Gemma L Carvill, Krysta L Engel, Aishwarya Ramamurthy, J Nicholas Cochran, Jolien Roovers, Hannah Stamberger, Nicholas Lim, Amy L Schneider, Georgie Hollingsworth, Dylan H Holder, Brigid M Regan, James Lawlor, Lieven Lagae, Berten Ceulemans, E Martina Bebin, John Nguyen, Gregory S Barsh, Sarah Weckhuysen, Miriam Meisler, Samuel E Berkovic Show all

AMERICAN JOURNAL OF HUMAN GENETICS | CELL PRESS | Published : 2018

Abstract

Developmental and epileptic encephalopathies (DEEs) are a group of severe epilepsies characterized by refractory seizures and developmental impairment. Sequencing approaches have identified causal genetic variants in only about 50% of individuals with DEEs.1-3 This suggests that unknown genetic etiologies exist, potentially in the ∼98% of human genomes not covered by exome sequencing (ES). Here we describe seven likely pathogenic variants in regions outside of the annotated coding exons of the most frequently implicated epilepsy gene, SCN1A, encoding the alpha-1 sodium channel subunit. We provide evidence that five of these variants promote inclusion of a "poison" exon that leads to reduced ..

View full abstract

Grants

Awarded by NIH


Awarded by National Human Genome Research Institute


Awarded by National Cancer Institute


Awarded by NIH (NINDS)


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL HUMAN GENOME RESEARCH INSTITUTE


Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE


Funding Acknowledgements

We thank the affected individuals and their families for participating in our research programs. G.L.C. is supported by the NIH (NINDS R00 NS089858) and the Junior Investigator Kevin's Fellows Award sponsored by the American Epilepsy Society and the Epilepsy Foundation. H.C.M. is supported by the NIH (NINDS R01 NS069605). I.E.S. and S.F.B. are supported by funding from the National Health and Medical Research Council of Australia. Work by authors at HudsonAlpha was supported by grants from the National Human Genome Research Institute (UM1HG007301) and National Cancer Institute (R01CA197139).